Cargando…

Correction to: Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111452/ https://www.ncbi.nlm.nih.gov/pubmed/36802969 http://dx.doi.org/10.1161/JAHA.121.027554

Ejemplares similares

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
por: Kingwell, Bronwyn A., et al.
Publicado: (2022)

Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
por: Gille, Andreas, et al.
Publicado: (2018)

Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A‐I and cholesterol efflux capacity in acute myocardial infarction patients
por: Zheng, Bo, et al.
Publicado: (2020)

CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
por: Gille, Andreas, et al.
Publicado: (2018)

Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison
por: Zheng, Bo, et al.
Publicado: (2022)

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity
por: Didichenko, Svetlana A., et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of CSL112
por: Ortega-Paz, Luis, et al.
Publicado: (2023)

Correction: Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux
Publicado: (2014)

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2018)

Antiatherosclerotic Effect of Canarium odontophyllum Miq. Fruit Parts in Rabbits Fed High Cholesterol Diet
por: Shakirin, Faridah Hanim, et al.
Publicado: (2012)

Effects of pre-eclampsia on HDL-mediated cholesterol efflux capacity after pregnancy
por: Kockx, Maaike, et al.
Publicado: (2022)

Correction to: Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study
por: Yubero-Serrano, Elena M., et al.
Publicado: (2021)

ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2017)

Uremia alters HDL composition and cholesterol efflux capacity
por: Holzer, Michael, et al.
Publicado: (2012)

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
por: Metzinger, Mark P., et al.
Publicado: (2020)

circDENND1B Participates in the Antiatherosclerotic Effect of IL-1β Monoclonal Antibody in Mouse by Promoting Cholesterol Efflux via miR-17-5p/Abca1 Axis
por: Xu, Fei, et al.
Publicado: (2021)

Antiobesogenic and Antiatherosclerotic Properties of Caralluma fimbriata Extract
por: Kamalakkannan, Soundararajan, et al.
Publicado: (2010)

RAGE and TLRs as Key Targets for Antiatherosclerotic Therapy
por: Olejarz, Wioletta, et al.
Publicado: (2018)

Cell-Based Models for Development of Antiatherosclerotic Therapies
por: Zakiev, Emile R., et al.
Publicado: (2017)

In Vivo Inflammation Does Not Impair ABCA1-Mediated Cholesterol Efflux Capacity of HDL
por: Franssen, Remco, et al.
Publicado: (2012)

Development and validation of novel automatable assay for cholesterol efflux capacity
por: Mutsuda, Yume, et al.
Publicado: (2023)

CD59 Underlines the Antiatherosclerotic Effects of C-Phycocyanin on Mice
por: Li, Bing, et al.
Publicado: (2013)

Pharmacokinetics and Safety of CSL112 (Apolipoprotein A‐I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function
por: Tortorici, Michael A., et al.
Publicado: (2018)

Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects
por: Kapoor, Shailendra
Publicado: (2012)

Antiatherosclerotic Potential of Clopidogrel: Antioxidant and Anti-Inflammatory Approaches
por: Hadi, Najah R., et al.
Publicado: (2013)

Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux
por: Daniil, Georgios, et al.
Publicado: (2013)

Effects of garlic on brachial endothelial function and capacity of plasma to mediate cholesterol efflux in patients with coronary artery disease
por: Mahdavi-Roshan, Marjan, et al.
Publicado: (2017)

Control of Angiogenesis by AIBP-mediated Cholesterol Efflux
por: Fang, Longhou, et al.
Publicado: (2013)

Lower than average HDL cholesterol efflux capacity in Lithuanian population
por: Kutkiene, Sandra, et al.
Publicado: (2019)

HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

The Signaling Pathways Involved in the Antiatherosclerotic Effects Produced by Chinese Herbal Medicines
por: Lu, Li, et al.
Publicado: (2018)

Sterol 27-hydroxylase gene dosage and the antiatherosclerotic effect of Rifampicin in mice
por: Zurkinden, Line, et al.
Publicado: (2018)

Antiatherosclerotic effect of dehydrocorydaline on ApoE(−/−) mice: inhibition of macrophage inflammation
por: Wen, Bin, et al.
Publicado: (2021)

Additive Effects of Drinking Habits and a Susceptible Genetic Polymorphism on Cholesterol Efflux Capacity
por: Matsumoto, Erika, et al.
Publicado: (2023)

Effects of Antirheumatic Treatment on Cell Cholesterol Efflux and Loading Capacity of Serum Lipoproteins in Spondylarthropathies
por: Hokstad, Ingrid, et al.
Publicado: (2022)

It’s Time to Reassess the High-Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation
por: Marsche, Gunther
Publicado: (2015)

Fungal CSL transcription factors
por: Převorovský, Martin, et al.
Publicado: (2007)

Targeted cholesterol efflux
por: Fang, Longhou, et al.
Publicado: (2013)

Correction: Activation of GPR55 Receptors Exacerbates oxLDL-Induced Lipid Accumulation and Inflammatory Responses, while Reducing Cholesterol Efflux from Human Macrophages
por: Lanuti, Mirko, et al.
Publicado: (2015)

Association of Cholesterol Efflux Capacity With Clinical Features of Metabolic Syndrome: Relevance to Atherosclerosis
por: Gall, Julie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r6e4dtja4k5lute6cmu3f7bg9i